July 2020, Drugs Monitor, Page 2

(22 July 2020) ACEIs/ARBs- No obvious influence on increasing the clinical severe situations of COVID‐19 patients with hypertension.

July 23, 2020

Efficacy of ACEIs/ARBs versus CCBs on the progression of COVID‐19 patients with hypertension in Wuhan: A hospital‐based retrospective cohort study https://doi.org/10.1002/jmv.26315 This retrospective single-center case series analyzed COVID-19 patients with hypertension, treated with ACEIs/ACEIs or CCBs . After PSM analysis,… Continue reading "(22 July 2020) ACEIs/ARBs- No obvious influence on increasing the clinical severe situations of COVID‐19 patients with hypertension."

(22 July 2020) Hydroxychloroquine- No clinical improvement observed

July 23, 2020

Clinical outcomes and adverse events in patients hospitalised with COVID ‐19, treated with off‐ label hydroxychloroquine and azithromycin https://doi.org/10.1111/bcp.14482 In a retrospective analysis of hospitalised patients that had a positive polymerase chain reaction (PCR) test for SARS-CoV-2 and received hydroxychloroquine… Continue reading "(22 July 2020) Hydroxychloroquine- No clinical improvement observed"

(20 July 2020) Hydroxychloroquine- combination of AZT and HCQ treatment effective in reducing the length of hospital stay

July 21, 2020

The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data https://doi.org/10.3906/sag-2005-82 In this retrospective and cross-sectional study, Eighty three patients were evaluated. The most common symptom was cough in 58… Continue reading "(20 July 2020) Hydroxychloroquine- combination of AZT and HCQ treatment effective in reducing the length of hospital stay"

(17 July 2020) Dexamethasone- resulted in lower 28-day mortality

July 18, 2020

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report https://www.nejm.org/doi/full/10.1056/NEJMoa2021436?query=featured_coronavirus In this controlled, open-label trial (RECOVERY ClinicalTrials.gov number, NCT04381936)comparing a range of possible treatments in patients who were hospitalized with Covid-19, patients were randomly assigned to receive oral or intravenous dexamethasone… Continue reading "(17 July 2020) Dexamethasone- resulted in lower 28-day mortality"

(17 July 2020) Darunavir- proportion of negative PCR results at day 7 was 46.7% in the DRV/c compared to 60% in control groups

July 18, 2020

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 https://doi.org/10.1093/ofid/ofaa241 In this single-center, randomized, and open-label trial, mild patients with COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 days on the top… Continue reading "(17 July 2020) Darunavir- proportion of negative PCR results at day 7 was 46.7% in the DRV/c compared to 60% in control groups"

(17 July 2020) Tocilizumab- clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88)

July 18, 2020

Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study https://doi.org/10.1002/jmv.26308 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ were retrospectively analyzed. Clinical status from day 0 (first… Continue reading "(17 July 2020) Tocilizumab- clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88)"

(17 July 2020) Hydroxychloroquine- did not substantially reduce symptom severity in outpatients with early, mild COVID-19

July 18, 2020

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial https://doi.org/10.7326/M20-4207 In a randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020 (ClinicalTrials.gov: NCT04308668) in symptomatic, non hospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk… Continue reading "(17 July 2020) Hydroxychloroquine- did not substantially reduce symptom severity in outpatients with early, mild COVID-19"

(15 July 2020) Tocilizumab- associated with rapid improvement in oxygenation and a faster decrease of CRP and WBC counts

July 16, 2020

Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study https://www.medrxiv.org/content/10.1101/2020.07.13.20149328v1 In this study (Clinical trial -RBR-3zdynp), patients with COVID 19 admitted in the ICU who were treated with tocilizumab plus standard care were enrolled and compared to… Continue reading "(15 July 2020) Tocilizumab- associated with rapid improvement in oxygenation and a faster decrease of CRP and WBC counts"

(15 July 2020) Hydroxychloroquine- not associated with reductions in 28-day mortality

July 16, 2020

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial https://doi.org/10.1101/2020.07.15.20151852 The preliminary results for the comparison of hydroxychloroquine vs. usual care alone from RECOVERY Trial NCT04381936 are presented. The primary outcome was 28-day… Continue reading "(15 July 2020) Hydroxychloroquine- not associated with reductions in 28-day mortality"

(14 July 2020) Proton Pump Inhibitors- Pre-hospitalization PPI use is associated with increased mortality and MV support

July 15, 2020

Prehospitalization Proton Pump Inhibitor (PPI) use and Clinical Outcomes in COVID-19 https://doi.org/10.1101/2020.07.12.20151084 The association between prehospitalization PPI use and clinical outcomes among hospitalized COVID-19 patients was studied. In the study, 15.6% of hospitalized COVID-19 patients were on PPIs at home.… Continue reading "(14 July 2020) Proton Pump Inhibitors- Pre-hospitalization PPI use is associated with increased mortality and MV support"

Month: July 2020